GlassScriptPhysician profile
Rachel White
NPI 1447633490
$4,304.70
in general payments reported to CMS, 2019-2025
31 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $120 · 2021: $602 · 2022: $370 · 2023: $489 · 2024: $980 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.37 |
| Education | $125.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $661.44 | 2020-2025 | Epsolay, Dysport, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $602.16 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $308.25 | 2019-2024 | Cabtreo |
| Lilly USA, LLC | $284.41 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $254.30 | 2019-2025 | Mavyret |
| Janssen Biotech, INC. | $231.89 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $220.57 | 2019-2025 | |
| Pfizer INC. | $187.27 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $175.75 | 2021-2025 | Absorica Ld, Winlevi |
| Mayne Pharma Commercial LLC | $162.58 | 2022-2025 | |
| Amgen INC. | $149.03 | 2020-2024 | Otezla |
| Leo Pharma INC. | $131.69 | 2021-2024 | Adbry |
| Dusa Pharmaceuticals, INC. | $124.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $100.39 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $79.89 | 2023-2025 | Zoryve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $76.13 | 2020-2024 | Klisyri, Seysara |
| Allergan, INC. | $70.45 | 2021-2022 | |
| Genzyme Corporation | $58.20 | 2019-2025 | |
| Epi Health, LLC | $56.29 | 2021-2022 | |
| Incyte Corporation | $50.99 | 2021-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $48.31 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $42.45 | 2021 | |
| Ucb, INC. | $40.80 | 2022-2023 | Briviact |
| Solta Medical, A Division of Bausch Health US, LLC | $37.54 | 2020-2021 | |
| Merz North America, INC. | $33.23 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $24.70 | 2025 | |
| Dermavant Sciences, INC. | $22.61 | 2023 | Vtama |
| Kerecis Limited | $20.61 | 2022 | |
| Organon LLC | $18.89 | 2025 | Vtama |
| Lnhc, INC | $17.27 | 2025 | Zelsuvmi |
| Biofrontera INC. | $11.62 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.